"renal cell cancer was historically considered to be one of the worst malignancies, and treatment was limited to cytokine therapy with a poor outlook," explained robert motzer, md, an attending physician at memorial sloan-kettering cancer center in new york city. however, a better understanding ...
Immuneering Corporation, a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recently announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabin...
Harnessing the power of the human immune system is steadily gaining recognition for its importance in the treatment of cancer.13BsAbs can simultaneously bind to two different antigens.14The most widely used BsAb is a bispecific T cell engager (BiTE), with one arm targeting CD3 on T cells and...
Considering the clinical bottleneck of poor response to conventional treatment as an opportunity, the basket trial identified the qualitative and quantitative proliferation-driven ability of the molecular phenotype in different tumor species and extended its application to pan-cancer. In contrast to traditio...
The deaths last month of two patients in a clinical trial testing a promising new type of cancer treatment are raising questions about the fate of therapies that use a patient’s own immune cells to fight off the disease. Juno Therapeutics, the Seatt
There are clinical trials underway in BCC in the perioperative and neoadjuvant treatment space. However, BCC trials are not as easy as CSCC trials because BCC has a discontinuous growth pattern, which means that you cannot well define the tumor bed, which needs to be excised after the intrale...
ELISPOT assay for monitoring cytotoxic T Lymphocytes (CTL) activity in cancer vaccine clinical trials Cells, 1 (2) (2012), pp. 111-126 Google Scholar Cited by (24) Primary role of type I interferons for the induction of functionally optimal antigen-specific CD8+ T cells in HIV infection 202...
The discovery of cancer immune surveillance and immunotherapy has opened up a new era of cancer treatment. Immunotherapies modulate a patient’s immune system to specifically eliminate cancer cells; thus, it is considered a very different approach from c
Thus, we created a liver-de-targeted sTGFβRIIFc- and LyP-1 peptide-expressing adenovirus (mHAdLyp.sT) with enhanced breast cancer cell tropism. Its safety and immune response features were profiled in the 4T1 model. Our data showed that the systemic administration of mHAdLyp.sT resulted ...
Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Mol Cancer. 2017;16(1):43. Article PubMed PubMed Central Google Scholar Hermann PC, Sainz B Jr. Pancreatic cancer stem cells: a state or an entity? Semin Cancer Biol. 2018;...